Literature DB >> 16087666

Regulation of the dynamics of hsp90 action on the glucocorticoid receptor by acetylation/deacetylation of the chaperone.

Patrick J M Murphy1, Yoshihiro Morishima, Jeffrey J Kovacs, Tso-Pang Yao, William B Pratt.   

Abstract

It is known that inhibition of histone deacetylases (HDACs) leads to acetylation of the abundant protein chaperone hsp90. In a recent study, we have shown that knockdown of HDAC6 by a specific small interfering RNA leads to hyperacetylation of hsp90 and that the glucocorticoid receptor (GR), an established hsp90 "client" protein, is defective in ligand binding, nuclear translocation, and gene activation in HDAC6-deficient cells (Kovacs, J. J., Murphy, P. J. M., Gaillard, S., Zhao, X., Wu, J-T., Nicchitta, C. V., Yoshida, M., Toft, D. O., Pratt, W. B., and Yao, T-P. (2005) Mol. Cell 18, 601-607). Using human embryonic kidney wild-type and HDAC6 (small interfering RNA) knockdown cells transiently expressing the mouse GR, we show here that the intrinsic properties of the receptor protein itself are not affected by HDAC6 knockdown, but the knockdown cytosol has a markedly decreased ability to assemble stable GR.hsp90 heterocomplexes and generate stable steroid binding activity under cell-free conditions. HDAC6 knockdown cytosol has the same ability to carry out dynamic GR.hsp90 heterocomplex assembly as wild-type cytosol. Addition of purified hsp90 to HDAC6 knockdown cytosol restores stable GR.hsp90 heterocomplex assembly to the level of wild-type cytosol. hsp90 from HDAC6 knockdown cytosol has decreased ATP-binding affinity, and it does not assemble stable GR.hsp90 heterocomplexes when it is a component of a purified five-protein assembly system. Incubation of knockdown cell hsp90 with purified HDAC6 converts the hsp90 to wild-type behavior. Thus, acetylation of hsp90 results in dynamic GR.hsp90 heterocomplex assembly/disassembly, and this is manifest in the cell as a approximately 100-fold shift to the right in the steroid dose response for gene activation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16087666     DOI: 10.1074/jbc.M506997200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  66 in total

1.  Alternative approaches to Hsp90 modulation for the treatment of cancer.

Authors:  Jessica A Hall; Leah K Forsberg; Brian S J Blagg
Journal:  Future Med Chem       Date:  2014-09       Impact factor: 3.808

Review 2.  GRP94: An HSP90-like protein specialized for protein folding and quality control in the endoplasmic reticulum.

Authors:  Michal Marzec; Davide Eletto; Yair Argon
Journal:  Biochim Biophys Acta       Date:  2011-11-03

3.  Automated hydrophobic interaction chromatography column selection for use in protein purification.

Authors:  Patrick J M Murphy; Orrin J Stone; Michelle E Anderson
Journal:  J Vis Exp       Date:  2011-09-21       Impact factor: 1.355

4.  A cell-based screen for inhibitors of protein folding and degradation.

Authors:  Frank Boschelli; Jennifer M Golas; Roseann Petersen; Vincent Lau; Lei Chen; Diane Tkach; Qiang Zhao; Dave S Fruhling; Hao Liu; Chaneun Nam; Kim T Arndt
Journal:  Cell Stress Chaperones       Date:  2010-08-19       Impact factor: 3.667

5.  Acetylation-mediated epigenetic regulation of glucocorticoid receptor activity: circadian rhythm-associated alterations of glucocorticoid actions in target tissues.

Authors:  Tomoshige Kino; George P Chrousos
Journal:  Mol Cell Endocrinol       Date:  2010-12-10       Impact factor: 4.102

Review 6.  Post-translational modifications of Hsp90 and translating the chaperone code.

Authors:  Sarah J Backe; Rebecca A Sager; Mark R Woodford; Alan M Makedon; Mehdi Mollapour
Journal:  J Biol Chem       Date:  2020-06-11       Impact factor: 5.157

7.  Heme-dependent activation of neuronal nitric oxide synthase by cytosol is due to an Hsp70-dependent, thioredoxin-mediated thiol-disulfide interchange in the heme/substrate binding cleft.

Authors:  Yoshihiro Morishima; Miranda Lau; Hwei-Ming Peng; Yoshinari Miyata; Jason E Gestwicki; William B Pratt; Yoichi Osawa
Journal:  Biochemistry       Date:  2011-07-21       Impact factor: 3.162

Review 8.  Selective Raf inhibition in cancer therapy.

Authors:  Vladimir Khazak; Igor Astsaturov; Ilya G Serebriiskii; Erica A Golemis
Journal:  Expert Opin Ther Targets       Date:  2007-12       Impact factor: 6.902

Review 9.  Psychiatric behaviors associated with cytoskeletal defects in radial neuronal migration.

Authors:  Toshifumi Fukuda; Shigeru Yanagi
Journal:  Cell Mol Life Sci       Date:  2017-05-17       Impact factor: 9.261

10.  Critical review of non-histone human substrates of metal-dependent lysine deacetylases.

Authors:  Tasha B Toro; Terry J Watt
Journal:  FASEB J       Date:  2020-08-30       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.